Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations.
Frost, Kevin J Hamilton, Ryan A Hughes, Stephen Jamieson, Conor Rafferty, Paul Troise, Oliver Jenkins, Abi
Frost, Kevin J
Hamilton, Ryan A
Hughes, Stephen
Jamieson, Conor
Rafferty, Paul
Troise, Oliver
Jenkins, Abi
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-11-07
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Updated European Committee on Antimicrobial Susceptibility Testing (EUCAST) amikacin breakpoints for Enterobacterales and Pseudomonas aeruginosa included revised dosing recommendations of 25-30 mg/kg to achieve key pharmacokinetic/pharmacodynamic parameters, higher than recommended in the British National Formulary. The objectives of this review were to identify clinical evidence for high-dose amikacin regimens and to determine drug exposures that are related to adverse events and toxicity.
Citation
Frost KJ, Hamilton RA, Hughes S, Jamieson C, Rafferty P, Troise O, Jenkins A. Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations. Eur J Hosp Pharm. 2023 Jul;30(4):189-195. doi: 10.1136/ejhpharm-2022-003421. Epub 2022 Nov 7.
Type
Article